Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Acalabrutinib-obinutuzumab in CLL: 3-year follow-up

Kerry Rogers • 19 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Obinutuzumab
ACE-CL-003

The combination of acalabrutinib with obinutuzumab was investigated for the treatment of chronic lymphocytic leukemia (CLL) in the Phase 1b/2 ACE-CL-003 study (NCT02296918). Here, Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the 3-year follow-up. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Kerry Rogers

2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
4:07
The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers • 8 Dec 2023
5:34
Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment
Kerry Rogers • 8 Dec 2023
1:18
Comorbidity and geriatric assessment tools in routine practice for CLL patients
Kerry Rogers • 7 Oct 2023

Related Videos

2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals